Liver grafts procured from donors after circulatory death have no increased risk of microthrombi formation

Cornelia J. Verhoeven, Tiarah C. Simon, Jeroen Jonge, Michael Doukas, Katharina Biermann, Herold J. Metselaar, Jan N. M. Ijzermans, Wojciech G. Polak – 19 August 2016 – Microthrombi formation provoked by warm ischemia and vascular stasis is thought to increase the risk of nonanastomotic strictures (NAS) in liver grafts obtained by donation after circulatory death (DCD). Therefore, potentially harmful intraoperative thrombolytic therapy has been suggested as a preventive strategy against NAS.

Macrovascular invasion is not an absolute contraindication for living donor liver transplantation

Kwang‐Woong Lee, Suk‐Won Suh, YoungRok Choi, Jaehong Jeong, Nam‐Joon Yi, Hyeyoung Kim, Kyung Chul Yoon, Suk Kyun Hong, Hyo‐Sin Kim, Kyung‐Bun Lee, Kyung‐Suk Suh – 19 August 2016 – The indication of liver transplantation (LT) for the treatment of advanced hepatocellular carcinoma (HCC) is expanding. However, portal vein tumor thrombus (PVTT) has been still accepted as an absolute contraindication. We experienced an unexpectedly good prognosis in selected patients. Therefore, we tried to identify the prognostic factors after LT for HCC with major PVTT.

Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for end‐stage liver disease score

Marie Sinclair, Paul J. Gow, Mathis Grossmann, Adam Shannon, Rudolf Hoermann, Peter W. Angus – 19 August 2016 – Low serum testosterone has been retrospectively associated with mortality in men on the liver transplant waiting list. The impact of testosterone deficiency on other outcomes has not previously been assessed. We conducted a single center prospective observational study of all men with cirrhosis seen between 2013 and 2014. Baseline data included sex hormone profile, Model for End‐Stage Liver Disease (MELD) score, and standard biochemistry.

Left lobe living donor liver transplantation in adults: What is the safety limit?

Toru Ikegami, Tomoharu Yoshizumi, Kazuhito Sakata, Hideaki Uchiyama, Norifumi Harimoto, Noboru Harada, Shinji Itoh, Akihisa Nagatsu, Yuji Soejima, Yoshihiko Maehara – 19 August 2016 – Small‐for‐size syndrome (SFSS) is the most significant cause of graft loss after living donor liver transplantation (LDLT), especially after left lobe (LL) LDLT in adults. The safety limit of applying LL‐LDLT in adults without severe SFSS with a high rate of lethality needs to be determined.

Subscribe to